Alteus Remedies Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 19-06-2024
- Paid Up Capital ₹ 0.10 M
as on 19-06-2024
- Company Age 3 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 31.50 Cr
as on 19-06-2024
- Revenue %
(FY 2023)
- Profit 27336.51%
(FY 2023)
- Net Worth 32005.50%
(FY 2023)
- Total Assets 346.28%
(FY 2023)
About Alteus Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹31.50 Cr.
Soma Dev and Debasish Mitra serve as directors at the Company.
- CIN/LLPIN
U24230JK2021PTC012262
- Company No.
012262
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Apr 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jammu
Industry
Company Details
- Location
Jammu, Jammu & Kashmir, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Alteus Remedies?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Soma Dev  | Director | 12-Apr-2021 | Current |
| Debasish Mitra | Director | 12-Apr-2021 | Current |
Financial Performance of Alteus Remedies.
Alteus Remedies Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 27336.51% increase in profit. The company's net worth Soared by an impressive increase of 32005.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Alteus Remedies?
In 2023, Alteus Remedies had a public holding of 0.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Alteus Biogenics Private LimitedActive 16 years 7 monthsSoma Dev and Debasish Mitra are mutual person
- Alteus Extra Pure Private LimitedActive 9 months 28 days
Soma Dev and Debasish Mitra are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 08 Jun 2023 | ₹12.00 Cr | Open |
Hdfc Bank Limited Creation Date: 25 Nov 2022 | ₹19.50 Cr | Open |
How Many Employees Work at Alteus Remedies?
Alteus Remedies has a workforce of 680 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alteus Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alteus Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
